<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">jsms</journal-id><journal-title-group><journal-title xml:lang="ru">Journal of Siberian Medical Sciences</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of Siberian Medical Sciences</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2542-1174</issn><publisher><publisher-name>Federal state budgetary educational institution of higher education "Novosibirsk state medical university" of  Ministry of Health of the Russian Federation (FSBEI HE NSMU MOH Russia)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31549/2542-1174-2023-7-2-7-16</article-id><article-id custom-type="elpub" pub-id-type="custom">jsms-908</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Факторы риска неблагоприятного исхода ВИЧ-инфекции, ассоциированной с цитопенией</article-title><trans-title-group xml:lang="en"><trans-title>Risk factors for an adverse outcome of HIV infection associated with cytopenia</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калашникова</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalashnikova</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Калашникова Дарья Владимировна – ассистент кафедры госпитальной терапии, эндокринологии; врач-гематолог отделения гематологии и химиотерапии</p><p>644099, г. Омск, ул. Ленина,12</p></bio><bio xml:lang="en"><p>Daria V. Kalashnikova – Assistant, Department of Hospital Therapy, Endocrinology; Hematologist, Department of Hematology and Chemotherapy</p><p>12, Lenina str., Omsk, 644099</p></bio><email xlink:type="simple">dashenkabar@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мордык</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mordyk</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мордык Анна Владимировна – д-р мед. наук, профессор, заведующий кафедрой фтизиатрии, фтизиохирургии и инфекционных болезней</p><p>Омск</p></bio><bio xml:lang="en"><p>Anna V. Mordyk – Dr. Sci. (Med.), Professor, Head, Department of Phthisiology, Phthisiosurgery and Infectious Diseases</p><p>Omsk</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пузырева</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Puzyreva</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Пузырева Лариса Владимировна – канд. мед. наук, доцент кафедры фтизиатрии, фтизиохирургии и инфекционных болезней; врач-инфекционист</p><p>Омск</p></bio><bio xml:lang="en"><p>Larisa V. Puzyreva – Dr. Sci. (Med.), Associate Professor, Department of Phthisiology, Phthisiosurgery and Infectious Diseases; Infectious Disease Physician</p><p>Omsk</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России; БУЗОО «Областная клиническая больница»<country>Россия</country></aff><aff xml:lang="en">Omsk State Medical University; Clinical Tuberculosis Dispensary No. 4<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России<country>Россия</country></aff><aff xml:lang="en">Omsk State Medical University<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России; БУЗОО «Клинический противотуберкулезный диспансер № 4»<country>Россия</country></aff><aff xml:lang="en">Omsk State Medical University; Regional Clinical Hospital<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>15</day><month>06</month><year>2023</year></pub-date><volume>0</volume><issue>2</issue><fpage>7</fpage><lpage>16</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Калашникова Д.В., Мордык А.В., Пузырева Л.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Калашникова Д.В., Мордык А.В., Пузырева Л.В.</copyright-holder><copyright-holder xml:lang="en">Kalashnikova D.V., Mordyk A.V., Puzyreva L.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://jsms.elpub.ru/jour/article/view/908">https://jsms.elpub.ru/jour/article/view/908</self-uri><abstract><sec><title>В в е д е н и е</title><p>В в е д е н и е . Появление гематологических аномалий с самого начала эпидемии ВИЧ-инфекции связывали с повышенным риском прогрессирования заболевания и смерти у этих пациентов.</p></sec><sec><title>Ц е л ь</title><p>Ц е л ь . Определение факторов риска неблагоприятного исхода у пациентов с ВИЧ-инфекцией и цитопенией.</p><p>М а т е р и а л ы и м е т о д ы . Проведен анализ гемограмм и миелограмм у 30 госпитализированных пациентов с ВИЧ-инфекцией и цитопенией. У всех пациентов в гемограмме имелась двух- или трехростковая цитопения (анемия и тромбоцитопения, анемия и лейкопения, панцитопения). Было выделено 2 группы пациентов: у 18 (60 %) госпитализация закончилась летальным исходом – 1-я группа (неблагоприятный исход заболевания); 12 (40 %) были выписаны из стационара – 2-я группа (благоприятный исход заболевания).</p></sec><sec><title>Р е з у л ь т а т ы</title><p>Р е з у л ь т а т ы . При оценке гемограмм у пациентов с ВИЧ-инфекцией и цитопениями с разным исходом заболевания статистически значимых различий не выявлено. Анализ клеточности костного мозга показал, что гипоклеточный и нормоклеточный костный мозг чаще регистрировался в миелограммах пациентов 1-й группы; гиперклеточный костный мозг у пациентов 1-й группы не выявляли, у пациентов 2-й группы определяли в 4 случаях (33.3 %). Клеточность эритроцитарного ростка чаще была снижена у пациентов 2-й группы, в норме и повышена – у пациентов 1-й группы. Гранулоцитарный росток чаще был угнетен у пациентов 1-й группы, был в норме у пациентов 2-й группы, раздражен чаще у пациентов 1-й группы. Мегакариоцитарный росток чаще имел сниженную клеточность у пациентов 1-й группы; нормоклеточность мегакараоцитарного ростка была у пациентов 2-й группы; гиперклеточности мегакариоцитарного ростка зарегистрировано в группах не было. При сравнении признаков миелодисплазии у 13 пациентов 1-й группы выявили признаки диспоэза.</p></sec><sec><title>З а к л ю ч е н и е</title><p>З а к л ю ч е н и е . У пациентов с ВИЧ-инфекцией и цитопенией по мере прогрессирования основного заболевания развиваются тяжелые гематологические нарушения, которые, в свою очередь, могут являться факторами риска неблагоприятного исхода ВИЧ-инфекции.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>I n t r o d u c t i o n</title><p>I n t r o d u c t i o n . The appearance of hematological abnormalities since the beginning of the HIV-infection epidemic has been associated with an increased risk of disease progression and death in these patients.</p></sec><sec><title>A i m</title><p>A i m . Determination of risk factors for an adverse outcome in patients with HIV infection and cytopenia.</p><p>M a t e r i a l s a n d m e t h o d s . Hemograms and myelograms were analyzed in 30 hospitalized patients with HIV infection and cytopenia. All patients had two- or three-lineage cytopenia according to hemogram (anemia and thrombocytopenia, anemia and leukopenia, pancytopenia). Two groups of patients were assigned: in 18 (60%) patients the hospitalization had fatal outcome – group 1 (adverse outcome of the disease); and 12 (40%) patients were discharged from the hospital – group 2 (favorable outcome of the disease).</p></sec><sec><title>R e s u l t s</title><p>R e s u l t s . While evaluating the hemograms in patients with HIV infection and cytopenia with diff erent outcomes of the disease, no statistically signifi cant diff erences were found. Analysis of the bone marrow cellularity showed that the hypocellular and normocellular bone marrow were more often recorded in myelograms of group 1 patients; hypercellular bone marrow was not detected in group 1 patients, in group 2 patients it was determined in 4 cases (33.3%). The cellularity of the erythroid lineage was more often decreased in patients of group 2, normal and increased – in patients of group 1. The granulocyte lineage was more often suppressed in patients of group 1, was normal in patients of group 2, stimulated more often in patients of group 1. The megakaryocyte lineage more often had a decreased cellularity in group 1 patients; normocellularity of the megakaryocyte lineage was in group 2 patients; hypercellularity of the megakaryocyte lineage was not registered in the study groups. When comparing the signs of myelodysplasia in 13 patients of group 1, signs of dyspoiesis were revealed.</p></sec><sec><title>C o n c l u s i o n</title><p>C o n c l u s i o n . In patients with HIV infection and cytopenia, as the underlying disease progresses, severe hematological disorders develop, which, in turn, may be risk factors for an adverse outcome of HIV infection.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>анемия</kwd><kwd>лейкопения</kwd><kwd>тромбоцитопения</kwd><kwd>миелодисплазия</kwd><kwd>ВИЧ-инфекция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>anemia</kwd><kwd>leukopenia</kwd><kwd>thrombocytopenia</kwd><kwd>myelodysplasia</kwd><kwd>HIV infection</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Durandt C., Potgieter J.C., Mellet J. et al. HIV and haematopoiesis // S. Afr. Med. J. 2019;109(8b):40-45. DOI: 10.7196/SAMJ.2019.v109i8b.13829.</mixed-citation><mixed-citation xml:lang="en">Durandt C., Potgieter J.C., Mellet J. et al. HIV and haematopoiesis. S. Afr. Med. J. 2019;109(8b):40-45. DOI: 10.7196/SAMJ.2019.v109i8b.13829.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Cao G., Wang Y., Wu Y. et al. Prevalence of anemia among people living with HIV: A systematic review and meta-analysis // EClinicalMedicine. 2022;44:101283. DOI: 10.1016/j.eclinm.2022.101283.</mixed-citation><mixed-citation xml:lang="en">Cao G., Wang Y., Wu Y. et al. Prevalence of anemia among people living with HIV: A systematic review and meta-analysis. EClinicalMedicine. 2022;44:101283. DOI: 10.1016/j.eclinm.2022.101283.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bhatta L., Klouman E., Deuba K. et al. Survival on antiretroviral treatment among adult HIV-infected patients in Nepal: a retrospective cohort study in Far-western region, 2006–2011 // BMC Infect. Dis. 2013;13:604. DOI: 10.1186/1471-2334-13-604.</mixed-citation><mixed-citation xml:lang="en">Bhatta L., Klouman E., Deuba K. et al. Survival on antiretroviral treatment among adult HIV-infected patients in Nepal: a retrospective cohort study in Far-western region, 2006–2011. BMC Infect. Dis. 2013;13:604. DOI: 10.1186/1471-2334-13-604.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Damtie S., Workineh L., Kiros T. et al. Hematological abnormalities of adult HIV-infected patients before and after initiation of highly active antiretroviral treatment at Debre Tabor Comprehensive Specialized Hospital, Northcentral Ethiopia: a cross-sectional study // HIV AIDS (Auckl). 2021;13:477-484. DOI: 10.2147/HIV.S308422.</mixed-citation><mixed-citation xml:lang="en">Damtie S., Workineh L., Kiros T. et al. Hematological abnormalities of adult HIV-infected patients before and after initiation of highly active antiretroviral treatment at Debre Tabor Comprehensive Specialized Hospital, Northcentral Ethiopia: a cross-sectional study. HIV AIDS (Auckl). 2021;13:477-484. DOI: 10.2147/HIV.S308422.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по гематологии: в 3 т. / Ю.Н. Андреев, З.С. Баркаган, А.Ю. Буланов и др. 3-е изд., перераб. и доп. М.: Ньюдиамед, 2005. Т. 3. 416 с.</mixed-citation><mixed-citation xml:lang="en">Yu.N. Andreev, Z.S. Barkagan, A.Y. Bulanov et al. (2005). Guide to Hematology: in 3 vol., 3rd ed., revised. Moscow: Newdiamed. Vol. 3. 416 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Akinbami A., Oshinaike O., Adeyemo T. et al. Hematologic abnormalities in treatment-naïve HIV patients // Infect. Dis. Res. Treat. 2010. Vol. 3. DOI: 10.4137/IDRT.S6033.</mixed-citation><mixed-citation xml:lang="en">Akinbami A., Oshinaike O., Adeyemo T. et al. Hematologic abnormalities in treatment-naïve HIV patients. Infect. Dis. Res. Treat. 2010. Vol. 3. DOI: 10.4137/IDRT.S6033.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Enawgaw B., Alem M., Addis Z., Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative crosssectional study // BMC Hematol. 2014;14(1):8. DOI: 10.1186/2052-1839-14-8.</mixed-citation><mixed-citation xml:lang="en">Enawgaw B., Alem M., Addis Z., Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative crosssectional study. BMC Hematol. 2014;14(1):8. DOI: 10.1186/2052-1839-14-8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Shen Y., Wang J., Wang Z. et al. A cross-sectional study of leukopenia and thrombocytopenia among Chinese adults with newly diagnosed HIV/AIDS // Biosci. Trends. 2015;9(2):91-96. DOI: 10.5582/bst.2015.01024.</mixed-citation><mixed-citation xml:lang="en">Shen Y., Wang J., Wang Z. et al. A cross-sectional study of leukopenia and thrombocytopenia among Chinese adults with newly diagnosed HIV/AIDS. Biosci. Trends. 2015;9(2):91-96. DOI: 10.5582/bst.2015.01024.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Канестри В.Г. Нарушение функционального состояния системы кроветворения у больных с ВИЧинфекцией // ВИЧ-инфекция и иммуносупрессии. 2017;9(2):7-15. DOI: 10.22328/2077-9828-2017-9-27-15.</mixed-citation><mixed-citation xml:lang="en">Kanestri V.G. Disorders of hemopoiesis in HIV patients. HIV infection and Immunosuppressive Disorders. 2017;9(2):7-15. DOI: 10.22328/2077-9828-2017-9-2-7-15. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ciccacci F., Lucaroni F., Latagliata R. et al. Hematologic alterations and early mortality in a cohort of HIV positive African patients // PLoS One. 2020;15(11):e0242068. DOI: 10.1371/journal.pone.0242068.</mixed-citation><mixed-citation xml:lang="en">Ciccacci F., Lucaroni F., Latagliata R. et al. Hematologic alterations and early mortality in a cohort of HIV positive African patients. PLoS One. 2020;15(11):e0242068. DOI: 10.1371/journal.pone.0242068.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Johannessen A., Naman E., Ngowi B.J. et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania // BMC Infect. Dis. 2008;8:52. DOI: 10.1186/1471-2334-8-52.</mixed-citation><mixed-citation xml:lang="en">Johannessen A., Naman E., Ngowi B.J. et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect. Dis. 2008;8:52. DOI: 10.1186/1471-2334-8-52.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
